Government decides to discontinue Central Allocation of Remdesivir
The Minister further informed that the Government has also increased the number of plants producing Remdesivir from 20 to 60 plants within a month.
The Minister further informed that the Government has also increased the number of plants producing Remdesivir from 20 to 60 plants within a month.
The availability of these drugs is being monitored by implementing the three-pronged strategy of Supply Chain Management, Demand Side Management and Affordability.
The allotment has been made for the States/UTs and State Governments and UTs have been asked to monitor proper distribution within the State/UT covering government and private hospitals as appropriate and in line with judicious use.
The gang would sell these fake injections as genuine Remdesivir, which is in high demand for treating COVID-19 patients, at excessive rates, a probe has revealed.
Each Remdesivir vial was sold for Rs 20,000 - Rs 25,000.
An updated Clinical Management Protocol for COVID-19 has been released by the Ministry of Health and Family Welfare on 13 June 2020 in which the drug Remdesivir has been included as an “investigational therapy” only for restricted emergency use purposes along with off label use of Tocilizumab and Convalescent Plasma.
The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak.
Indian companies Mumbai-headquartered Cipla, Hyderabad-based Hetero Labs and Noida-based Jubilant Life Sciences has signed up the agreement to manufacture the drug and to sell it in 127 countries.
The scrip rallied 4.99 per cent to Rs 429.95 on the BSE, and 4.99 per cent to Rs 428.55 on the NSE.
Indian pharmaceutical manufacturers, Jubilant Life Sciences, Cipla Ltd, Hetero Labs Ltd and Mylan and Pakistani firm Ferozsons Laboratories have signed the commercial agreement that allows the companies to manufacture remdesivir for distribution in 127 countries, including India.
